RxDoctor Payments Data

Nancy Folley

Family · Danville, VANPI 1154814119

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by AbbVie at 57.9% of the total. Reporting peaked in 2021 at $12,713 and has fallen 73.7% since, to $3,342 in 2025. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,886in general payments, 2019–2025

Across 1,001 payments — averaging $36.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$21K
  • Biogen$2K
  • EMD Serono, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Acadia Pharmaceuticals Inc$1K
  • Novartis$772
  • plus $9K from 38 others

What the payments were for

  • Speaking & faculty fees$19,21952%
  • Travel & lodging$1790%
  • Food & beverage$17,10146%
  • Education$3871%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,886 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate31$195,305
Nurtec OdtRimegepant Sulfate79$147,040
MayzentSiponimod12$114,233
UbrelvyUbrogepant77$109,230
QuliptaAtogepant87$106,565
Austedo XrDeutetrabenazine16$95,403
AptiomEslicarbazepine Acetate48$87,347
Aimovig AutoinjectorErenumab-Aooe39$34,009
RexultiBrexpiprazole23$33,925
XcopriCenobamate26$30,929
BriviactBrivaracetam22$29,713
Nucynta ErTapentadol Hcl14$24,903
Emgality PenGalcanezumab-Gnlm35$24,165
Ajovy AutoinjectorFremanezumab-Vfrm15$24,023
Lacosamide89$10,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$21,375$215,795164 claims
Neurocrine Biosciences, Inc.Ingrezza$1,083$195,30531 claims
PfizerNurtec Odt$488$147,04079 claims
NovartisMayzent$772$114,23312 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$649$95,40316 claims
Sunovion Pharmaceuticals Inc.Aptiom$202$87,34748 claims
Otsuka America Pharmaceutical, Inc.Rexulti$360$33,92523 claims
SK Life Science, Inc.Xcopri$601$30,92926 claims
UCB, Inc.Briviact$749$29,71322 claims
Corium, LLCAdlarity$163$5,31512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Danville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →